News

Understanding Eli Lilly's Unusual Options Activity Today

Understanding Eli Lilly's Unusual Options Activity Today

Eli Lilly's Options Activity Analysis

Eli Lilly has recently caught the attention of investors as distinctive bearish activity has been observed among financial giants. By analyzing options history for Eli Lilly (NYSE: LLY), we discovered a total of 84 unusual trades that reflect diverse market sentiments.

Current Market Sentiment

In examining this trading activity, it's evident that 27% of traders exhibited a bullish outlook, while a significant 51% leaned bearish. The trades consisted of 26 puts valued at $2,090,541, and 58 calls worth an impressive $10,418,102.

Price Movement Expectations

Considering the trading volume and open interest on these options, it appears that major investors are anticipating Eli Lilly's price to fluctuate within the ranges of $520.0 to $1400.0 over the last three months. This range provides a comprehensive view of potential price actions that traders are keenly observing.

Volume and Open Interest Insights

Monitoring both volume and open interest is a reliable approach for conducting due diligence on Eli Lilly's stock. Analyzing this data facilitates the tracking of liquidity and interest regarding the options corresponding to specific strike prices.

Recent Activity Overview

In the past 30 days, the volume and open interest surrounding Eli Lilly’s options have seen notable variations within the established strike price range of $520.0 to $1400.0. The following sections provide valuable insights into this trading landscape.

Summary of Options Activity

Here is a concise summary of options activity for Eli Lilly:

  • LLY Call: A striking example indicates a trade executed with a sentiment categorized as neutral, where the traded price was noted at $248.0 against an ask of $253.0.
  • Another notable bearish call revealed an executed trade priced at $152.0 amidst a backdrop of fluctuating market conditions.
  • A more bullish scenario for $164.24 was noted, aligning with a target indicated by an average of ratings from experts, optimizing the stock evaluation.

About Eli Lilly

Eli Lilly is a leading pharmaceutical company specializing in areas such as neuroscience, cancer, cardiometabolic, and immunology. The company’s product lineup includes Verzenio for oncology, Mounjaro, Jardiance, and Trulicity for managing cardiometabolic disorders, alongside Taltz and Olumiant for immunological treatments.

Current Stock Performance

The company’s current stock performance indicates a trading volume of 1,643,178, showing a decrease of 2.73% at $1074.19. The RSI indicators are hinting that the stock might be experiencing an overbought status.

Analysts’ Perspectives on Eli Lilly

Several experts have been vocal regarding Eli Lilly’s stock opportunities. Recently, five analysts have released their ratings with an average target price of $1195.8. Here’s some insight:

  • Citigroup maintains a Buy rating, targeting a price of $1500.
  • Leerink Partners upgraded their stance to Outperform, adjusting their target to $1104.
  • BMO Capital sustains an Outperform rating with a $1100 target.
  • Morgan Stanley keeps an Overweight rating, eyes a price of $1290.
  • Cantor Fitzgerald holds an Overweight rating, targeting $985.

Risk Considerations in Options Trading

When it comes to options trading, it is essential to recognize that they pose greater risks compared to straightforward stock trading. However, they also offer higher profit potentials. To navigate this landscape, traders should focus on education, scaling their involvement in trades, and utilizing multiple indicators while closely monitoring the market trends.

Stay Updated

If you are interested in keeping abreast of the latest in options trading for Eli Lilly, there are real-time options trades alerts available through dedicated platforms, ensuring you're well-informed in this dynamic environment.

Frequently Asked Questions

What unusual options activity has been observed for Eli Lilly?

Recent analysis shows 84 notable trades, with a significant portion being bearish in nature.

What are the expectations regarding Eli Lilly's stock price?

Major investors are targeting a price range between $520.0 to $1400.0 in the coming months.

What do the analysts say about Eli Lilly's stock?

Analysts have an average target price of $1195.8 with several maintaining bullish stances.

How much is Eli Lilly's stock trading currently?

As of now, Eli Lilly's stock is trading at $1074.19 with a noted decrease of 2.73%.

What strategies are recommended for options trading?

Educating oneself, managing risk, and closely following market trends are vital for success in options trading.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 27

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 95

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 196

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 118

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 51

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Science Applications Intl's Earnings Preview: Key Insights Ahead

Updated Category News Views 170

Understanding Science Applications Intl's Earnings Preview Science Applications Intl (NYSE: SAIC) is gearing up for its quarterly earnings announcement. Investors are eager to see how the company performs and whether it meets analysts' expectations. What to Anticipate Analysts project Science Applications Intl will report an earnings per share (EPS) of $2.11, which could...

Continue Reading
Innovative Aerogels Paving the Path for Water Harvesting Solutions

Updated Category News Views 285

Introduction to Atmospheric Water Harvesting The world faces an alarming freshwater crisis, with projections indicating that vast segments of the population are at risk of water scarcity. In response, researchers have innovatively turned to atmospheric water harvesting, particularly highlighting the advancements made by the National University of Singapore (NUS). They...

Continue Reading
Class Action Lawsuit Alert for Tronox Holdings Plc Investors

Updated Category News Views 131

Insights into the Tronox Holdings Class Action Lawsuit Investors in Tronox Holdings Plc (NYSE: TROX) should be aware of a class action lawsuit initiated against the company. This legal action centers around allegations of potential securities fraud and improper business practices by Tronox and some of its leadership. The firm Pomerantz LLP, known for its expertise in...

Continue Reading
Rapport Therapeutics Set to Showcase Innovations in Healthcare

Updated Category News Views 128

Rapport Therapeutics to Attend Major Investor Conferences BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology firm at the forefront of developing small molecule precision medicines targeting neurological and psychiatric disorders, has expressed its excitement about participating in two notable investor conferences soon. Details of Upcoming...

Continue Reading
Northwestern Mutual Achieves Unmatched Financial Strength Ratings

Updated Category News Views 353

Northwestern Mutual Achieves Elite Financial Ratings for 35 Years For an impressive 35 years, Northwestern Mutual has consistently earned top financial strength ratings from the nation's leading rating agencies. This recognition underscores the company’s commitment to maintaining a robust financial foundation, which plays a crucial role in their ability to serve clients...

Continue Reading